Table of Contents

Chapter 1 Overview of Hemoglobinopathies

• 1.1 Definition of Hemoglobinopathies in This Report
• 1.2 Commercial Types of Hemoglobinopathies
  • 1.2.1 Thalassemia
  • 1.2.2 Sickle Cell Disease
  • 1.2.3 Other Hb Variants Diseases
• 1.3 Downstream Application of Hemoglobinopathies
  • 1.3.1 Blood Testing
  • 1.3.2 Genetic Testing
  • 1.3.3 Pre-Implantation Genetic Diagnosis (PGD)
  • 1.3.4 Others
• 1.4 Development History of Hemoglobinopathies
• 1.5 Market Status and Trend of Hemoglobinopathies 2013-2023
  • 1.5.1 Global Hemoglobinopathies Market Status and Trend 2013-2023
  • 1.5.2 Regional Hemoglobinopathies Market Status and Trend 2013-2023

Chapter 2 Global Market Status and Forecast by Regions

• 2.1 Market Development of Hemoglobinopathies 2013-2017
• 2.2 Production Market of Hemoglobinopathies by Regions
  • 2.2.1 Production Volume of Hemoglobinopathies by Regions
  • 2.2.2 Production Value of Hemoglobinopathies by Regions
• 2.3 Demand Market of Hemoglobinopathies by Regions
• 2.4 Production and Demand Status of Hemoglobinopathies by Regions
  • 2.4.1 Production and Demand Status of Hemoglobinopathies by Regions 2013-2017
  • 2.4.2 Import and Export Status of Hemoglobinopathies by Regions 2013-2017

Chapter 3 Global Market Status and Forecast by Types

• 3.1 Production Volume of Hemoglobinopathies by Types
• 3.2 Production Value of Hemoglobinopathies by Types
• 3.3 Market Forecast of Hemoglobinopathies by Types

Chapter 4 Global Market Status and Forecast by Downstream Industry

• 4.1 Demand Volume of Hemoglobinopathies by Downstream Industry
• 4.2 Market Forecast of Hemoglobinopathies by Downstream Industry

Chapter 5 Market Driving Factor Analysis of Hemoglobinopathies

• 5.1 Global Economy Situation and Trend Overview
• 5.2 Hemoglobinopathies Downstream Industry Situation and Trend Overview

Chapter 6 Hemoglobinopathies Market Competition Status by Major Manufacturers

• 6.1 Production Volume of Hemoglobinopathies by Major Manufacturers
• 6.2 Production Value of Hemoglobinopathies by Major Manufacturers
• 6.3 Basic Information of Hemoglobinopathies by Major Manufacturers
  • 6.3.1 Headquarters Location and Established Time of Hemoglobinopathies Major Manufacturer
  • 6.3.2 Employees and Revenue Level of Hemoglobinopathies Major Manufacturer
• 6.4 Market Competition News and Trend
  • 6.4.1 Merger, Consolidation or Acquisition News
  • 6.4.2 Investment or Disinvestment News
  • 6.4.3 New Product Development and Launch

Chapter 7 Hemoglobinopathies Major Manufacturers Introduction and Market Data

• 7.1 Emmaus Life Sciences Inc.
  • 7.1.1 Company profile
  • 7.1.2 Representative Hemoglobinopathies Product
  • 7.1.3 Hemoglobinopathies Sales, Revenue, Price and Gross Margin of Emmaus Life Sciences Inc.
• 7.2 Prolong Pharmaceuticals
  • 7.2.1 Company profile
  • 7.2.2 Representative Hemoglobinopathies Product
  • 7.2.3 Hemoglobinopathies Sales, Revenue, Price and Gross Margin of Prolong Pharmaceuticals
• 7.3 Sangamo Therapeutics Inc.
  • 7.3.1 Company profile
  • 7.3.2 Representative Hemoglobinopathies Product
  • 7.3.3 Hemoglobinopathies Sales, Revenue, Price and Gross Margin of Sangamo Therapeutics Inc.
• 7.4 Alnylam Pharmaceuticals
  • 7.4.1 Company profile
  • 7.4.2 Representative Hemoglobinopathies Product
  • 7.4.3 Hemoglobinopathies Sales, Revenue, Price and Gross Margin of Alnylam Pharmaceuticals
• 7.5 Gamida Cell
  • 7.5.1 Company profile
  • 7.5.2 Representative Hemoglobinopathies Product
  • 7.5.3 Hemoglobinopathies Sales, Revenue, Price and Gross Margin of Gamida Cell
• 7.6 Sanofi
  • 7.6.1 Company profile
  • 7.6.2 Representative Hemoglobinopathies Product
  • 7.6.3 Hemoglobinopathies Sales, Revenue, Price and Gross Margin of Sanofi
• 7.7 Bluebird Bio
  • 7.7.1 Company profile
  • 7.7.2 Representative Hemoglobinopathies Product
  • 7.7.3 Hemoglobinopathies Sales, Revenue, Price and Gross Margin of Bluebird Bio
• 7.8 Global Blood Therapeutics
  • 7.8.1 Company profile
  • 7.8.2 Representative Hemoglobinopathies Product
  • 7.8.3 Hemoglobinopathies Sales, Revenue, Price and Gross Margin of Global Blood Therapeutics
• 7.9 Celgene Corporation
  • 7.9.1 Company profile
  • 7.9.2 Representative Hemoglobinopathies Product
  • 7.9.3 Hemoglobinopathies Sales, Revenue, Price and Gross Margin of Celgene Corporation

Chapter 8 Upstream and Downstream Market Analysis of Hemoglobinopathies

• 8.1 Industry Chain of Hemoglobinopathies
• 8.2 Upstream Market and Representative Companies Analysis
• 8.3 Downstream Market and Representative Companies Analysis

Chapter 9 Cost and Gross Margin Analysis of Hemoglobinopathies

• 9.1 Cost Structure Analysis of Hemoglobinopathies
• 9.2 Raw Materials Cost Analysis of Hemoglobinopathies
• 9.3 Labor Cost Analysis of Hemoglobinopathies
• 9.4 Manufacturing Expenses Analysis of Hemoglobinopathies

Chapter 10 Marketing Status Analysis of Hemoglobinopathies

• 10.1 Marketing Channel
  • 10.1.1 Direct Marketing
  • 10.1.2 Indirect Marketing
  • 10.1.3 Marketing Channel Development Trend
• 10.2 Market Positioning
  • 10.2.1 Pricing Strategy
  • 10.2.2 Brand Strategy
  • 10.2.3 Target Client
• 10.3 Distributors/Traders List

Chapter 11 Report Conclusion

Chapter 12 Research Methodology and Reference

• 12.1 Methodology/Research Approach
  • 12.1.1 Research Programs/Design
  • 12.1.2 Market Size Estimation
  • 12.1.3 Market Breakdown and Data Triangulation
• 12.2 Data Source
  • 12.2.1 Secondary Sources
  • 12.2.2 Primary Sources

Report Summary

Hemoglobinopathies -Global Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Hemoglobinopathies  industry, standing on the readers’ perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:

Worldwide and Regional Market Size of Hemoglobinopathies  2013-2017, and development forecast 2018-2023
Main manufacturers/suppliers of Hemoglobinopathies  worldwide, with company and product introduction, position in the Hemoglobinopathies  market
Market status and development trend of Hemoglobinopathies  by types and applications
Cost and profit status of Hemoglobinopathies , and marketing status
Market growth drivers and challenges

The report segments the global Hemoglobinopathies  market as:

Global Hemoglobinopathies  Market: Regional Segment Analysis (Regional Production Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
North America
Europe
China
Japan
Rest APAC
Latin America

Global Hemoglobinopathies  Market: Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Thalassemia
Sickle Cell Disease
Other Hb Variants Diseases

Global Hemoglobinopathies  Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Blood Testing
Genetic Testing
Pre-Implantation Genetic Diagnosis (PGD)
Others

Global Hemoglobinopathies  Market: Manufacturers Segment Analysis (Company and Product introduction, Hemoglobinopathies  Sales Volume, Revenue, Price and Gross Margin):
Emmaus Life Sciences Inc.
Prolong Pharmaceuticals
Sangamo Therapeutics Inc.
Alnylam Pharmaceuticals
Gamida Cell
Sanofi
Bluebird Bio
Global Blood Therapeutics
Celgene Corporation

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.